Frazier Life Sciences Management as of June 30, 2024
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 49 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 11.0 | $235M | 12M | 19.21 | |
| Mirum Pharmaceuticals (MIRM) | 10.4 | $222M | 6.5M | 34.19 | |
| Krystal Biotech (KRYS) | 8.5 | $182M | 989k | 183.64 | |
| Hillevax (HLVX) | 7.2 | $154M | 11M | 14.46 | |
| Phathom Pharmaceuticals (PHAT) | 4.9 | $104M | 10M | 10.30 | |
| Rhythm Pharmaceuticals (RYTM) | 4.6 | $97M | 2.4M | 41.06 | |
| Bridgebio Pharma (BBIO) | 4.3 | $92M | 3.6M | 25.33 | |
| Arcutis Biotherapeutics (ARQT) | 3.8 | $82M | 8.8M | 9.30 | |
| Disc Medicine (IRON) | 3.7 | $79M | 1.8M | 45.07 | |
| Vaxcyte (PCVX) | 3.7 | $79M | 1.0M | 75.51 | |
| Edgewise Therapeutics (EWTX) | 3.1 | $67M | 3.7M | 18.01 | |
| Anaptysbio Inc Common (ANAB) | 2.5 | $54M | 2.2M | 25.06 | |
| Verona Pharma Sponsored Ads (VRNA) | 2.2 | $48M | 3.3M | 14.46 | |
| Kalvista Pharmaceuticals (KALV) | 2.0 | $43M | 3.7M | 11.78 | |
| Tarsus Pharmaceuticals (TARS) | 2.0 | $43M | 1.6M | 27.18 | |
| Revolution Medicines (RVMD) | 1.8 | $39M | 998k | 38.81 | |
| Erasca (ERAS) | 1.8 | $38M | 16M | 2.36 | |
| Agios Pharmaceuticals (AGIO) | 1.8 | $38M | 872k | 43.12 | |
| Soleno Therapeutics (SLNO) | 1.7 | $36M | 876k | 40.80 | |
| Rocket Pharmaceuticals (RCKT) | 1.6 | $34M | 1.6M | 21.53 | |
| Savara (SVRA) | 1.5 | $33M | 8.2M | 4.03 | |
| Oric Pharmaceuticals (ORIC) | 1.4 | $29M | 4.1M | 7.07 | |
| Cg Oncology (CGON) | 1.1 | $24M | 770k | 31.57 | |
| Pepgen (PEPG) | 1.1 | $24M | 1.5M | 15.96 | |
| Merus N V (MRUS) | 1.0 | $22M | 373k | 59.17 | |
| Trevi Therapeutics (TRVI) | 1.0 | $22M | 7.4M | 2.98 | |
| Silence Therapeutics Ads (SLN) | 1.0 | $22M | 1.1M | 19.00 | |
| Ultragenyx Pharmaceutical (RARE) | 0.8 | $18M | 425k | 41.10 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.8 | $16M | 4.6M | 3.48 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.8 | $16M | 393k | 40.89 | |
| Mereo Biopharma Group Spon Ads (MREO) | 0.7 | $16M | 4.4M | 3.60 | |
| Immatics SHS (IMTX) | 0.6 | $13M | 1.2M | 11.62 | |
| Tyra Biosciences (TYRA) | 0.6 | $13M | 832k | 15.99 | |
| Macrogenics (MGNX) | 0.6 | $13M | 3.0M | 4.25 | |
| Applied Therapeutics (APLT) | 0.5 | $11M | 2.3M | 4.67 | |
| Puma Biotechnology (PBYI) | 0.5 | $10M | 3.1M | 3.26 | |
| 89bio (ETNB) | 0.4 | $8.0M | 1.0M | 8.01 | |
| Elevation Oncology (ELEV) | 0.4 | $8.0M | 3.0M | 2.70 | |
| Cogent Biosciences (COGT) | 0.4 | $7.9M | 937k | 8.43 | |
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $7.6M | 470k | 16.25 | |
| Arvinas Ord (ARVN) | 0.4 | $7.6M | 285k | 26.62 | |
| Adverum Biotechnologies Com New (ADVM) | 0.3 | $7.3M | 1.1M | 6.86 | |
| Allogene Therapeutics (ALLO) | 0.3 | $6.7M | 2.9M | 2.33 | |
| An2 Therapeutics (ANTX) | 0.2 | $4.5M | 2.1M | 2.15 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.2 | $4.4M | 500k | 8.72 | |
| Design Therapeutics (DSGN) | 0.2 | $4.0M | 1.2M | 3.35 | |
| Immunocore Hldgs Ads (IMCR) | 0.2 | $3.7M | 109k | 33.89 | |
| Metagenomi (MGX) | 0.0 | $1.0M | 246k | 4.08 | |
| Aclaris Therapeutics (ACRS) | 0.0 | $291k | 264k | 1.10 |
